EUCTR2017-002919-33-DE进行中（未招募）1 期
Phase IV, open-label, randomized study to enrol healthy adult volunteers, naïve to any previous meningococcal vaccination or meningococcal disease, aged 18-50 years, to be either vaccinated with GSK MenACWY vaccine (Menveo) or GSK rMenB+OMV NZ vaccine (Bexsero), and serve as donors of human blood for conversion into serum to use in the development, qualification, validation and maintenance of immunological assays and to support preclinical research activities, clinical development and life cycle management of GSK Biologicals vaccines. - MENB REC 2ND GEN-079 HBS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,020
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •Written informed consent obtained from the subject prior to performing any study specific procedure.
- •A male or female between, and including, 18 and 50 years of age at the time of the first study visit.
- •Healthy subjects as established by medical history and clinical examination before entering into the study. Healthy subjects with no medical conditions that, in the opinion of the investigator, prevents the subject from participating in the study.
- •Subjects must weigh at least 110 pounds (50 kg), but not to present obesity (BMI < 32kg/m2).
- •Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •?has practiced adequate contraception for 30 days prior to vaccination, and
- •?has a negative pregnancy test on the day of vaccination and
- •?has agreed to continue adequate contraception during the entire treatment period and for 1 month, after completion of the vaccination series.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1020
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Progressive, unstable or uncontrolled clinical conditions.
- •Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.
- •Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
- •Abnormal function of the immune system resulting from:
- •?Clinical conditions.
- •?Systemic administration of corticosteroids (PO/IV/IM) within 90 days prior to informed consent.
- •?Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.
- •Received immunoglobulins or any blood products within 180 days prior to informed consent.
- •Received an investigational or non-registered medicinal product within 30 days prior to informed consent.
- •Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
- •Any history of meningococcal vaccination or meningococcal and gonorrhoea diseases.
- •Enrolment in any activity requiring a blood donation greater than 50 mL during the period starting 30 days before the first study visit (Day -83, Day -60 or Day -30) or for the duration of the study period.
- •Administration of long-acting immune-modifying drugs at any time during the study period
- •Subjects with blood disorders.
- •Subjects with a history of difficulty in providing blood samples
- •Any antibiotic intake 7 days prior to blood collection.
- •Subjects who donated >450 mL of blood within 60 days prior to any blood collection visits.
- •Subjects who lost >200 mL during a single apheresis or who lost red blood cells on more than one occasion during apheresis within the previous 60 days.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product
- •Ongoing anaemia as indicated by haemoglobin values below the lower limit of the laboratory-specified reference range. If the finger prick method demonstrates an anaemia, no further protocol procedures will be performed, and the subject will be referred for appropriate medical management. The subject may participate in this study following therapy and evidence that the anaemia has been resolved.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •Pregnant or lactating female.
- •Female planning to become pregnant or planning to discontinue contraceptive precautions.
- •Any confirmed or suspected immunosuppressive or immunodeficiency condition based on medical history and physical examination
- •Family history of congenital or hereditary immunodeficiency.
- •Serious chronic illness.
- •History of chronic alcohol consumption and/or drug abuse.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate the effects of Fydrane® and standard protocol on ocular surface after cataract surgery.CataractsMedDRA version: 20.0 Level: PT Classification code 10007739 Term: Cataract System Organ Class: 10015919 - Eye disordersMedDRA version: 20.0 Level: PT Classification code 10063797 Term: Cataract operation System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2017-003277-34-ESaboratoires Théa50
尚未招募
4 期
A clinical trial to study the effect of herbal hair treatment on hair lossCTRI/2020/04/024543Allen Laboratories Limited
进行中（未招募）
1 期
An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapyEUCTR2019-000817-35-GBAlmirall250
进行中（未招募）
1 期
An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapyModerate to severe chronic plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2019-000817-35-NLAlmirall250
进行中（未招募）
1 期
An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapyModerate to severe chronic plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2019-000817-35-DEAlmirall250